重症肌无力病例回顾分析及健脾祛湿方对肌细胞损伤作用的实验研究
|
摘要
目的:
重症肌无力是乙酰胆碱能运动神经元与骨骼肌之间突触功能障碍性疾病,其发病多归属于抗乙酰胆碱受体抗体的作用导致神经肌肉接头传递障碍。此外目前研究还发现,在重症肌无力的发病中往往可见肌细胞的损伤,如:线粒体的形态异常、呼吸链复合体-1缺失等等,无法用神经肌肉接头传递障碍进行简单地解释。另一方面,导师刘友章教授在临床上应用健脾祛湿方治疗重症肌无力取得了良好的疗效。因此本研究拟进行临床回顾性调查,总结重症肌无力诊治的现状,观察健脾益气方药对MG的影响及作用,并通过复制实验性自身免疫性重症肌无力动物模型,研究重症肌无力的肌细胞损伤的病理特点与其发病机制,对重症肌无力的发病机制进行补充,观察健脾祛湿方对其影响作用,探讨健脾祛湿方对防治重症肌无力的肌细胞损伤的作用机制,为中西医结合治疗重症肌无力的治疗方案提供理论指导。
方法:
本研究包括文献研究及实验研究。文献研究中,从祖国医学对重症肌无力的认识、现代医学对重症肌无力的研究、重症肌无力与肌细胞损伤的关系、重症肌无力模型的研究等四方面对重症肌无力的研究进行了详细的文献整理和总结。实验研究由两部分组成:第一部分是临床病历回顾研究,拟查阅广州中医药大学第一附属医院病案室近10年来重症肌无力的住院病历,调查分析重症肌无力住院病人的病因、病程、症状、诱因、并发症及治疗等,并进行统计学分析,观察健脾益气方药对重症肌无力的疗效,总结重症肌无力的诊治现状。第二部分是动物实验研究,选用SPF级Lewis大鼠45只,随机选取6只作为正常组(A组)正常饲养,其余39只以皮下注射人工合成的鼠源性乙酰胆碱α亚基97～116肽段来制作实验性自身免疫性重症肌无力动物模型,第6周末造模大鼠剩下36只,经肌电图检测后,确定成模32只,再将其随机分为模型对照组(B组)、强的松组(C组)、健脾祛湿方高剂量组(D组)、健脾祛湿方低剂量组(E组),每组各8只。成模2周后开始经灌胃药物干预,A、B组给予等容量生理盐水灌胃,C组给予强的松,剂量为5.4mg/kg体重·d,D、E组给予健脾祛湿方,剂量分别为37.6g/kg体重·d、18.8g/kg体重·d。以上各组灌胃液体量为10ml/kg体重,每日给药一次,其浓度及等效剂量按体重折算,共给药4周。实验结束后观察大鼠一般情况及体重、Lennon评分变化,观察肌肉线粒体及神经肌肉接头处超微结构的变化,并检测肌肉线粒体的DNA糖基化酶的表达、ATP含量、细胞色素氧化酶的活性及含量的改变。
结果:
1.临床回顾性研究:
1.1重症肌无力住院患者男女比例1:1.23,发病高峰在31到50岁之间,大部分(72.73%)的病人病程在5年以下,分型以中度全身型为主;
1.2积极预防控制感染,充分休息,避免劳累,规律服药,不擅自改变药量,饮食健康,调畅情志对MG病情的控制和恢复具有重要作用;
1.3重症肌无力患者的舌脉以淡舌、白苔、细脉最多见,反映其主要病机为脾肾虚损,湿浊内停;
1.4对重症肌无力患者中药使用频次分析表明:药物使用以补气健脾药为主,辅以利湿、补肾、活血、强筋药,符合对重症肌无力主要病机的分析。
2.动物实验研究:
2.1中药干预(健脾祛湿方)可改善实验性自身免疫性重症肌无力模型大鼠的肌无力症状、皮毛色泽;治疗前后体重比较,B组体重稍下降,C组略增加,但均无明显差异(P＞0.05),D、E组体重均较治疗前明显增加(P＜0.05),D、E组间比较无明显差异(P＜0.05)。
2.2肌肉线粒体及神经肌肉接头处电镜观察:实验性自身免疫性重症肌无力模型大鼠存在肌纤维稀疏、紊乱,线粒体减少,神经肌肉接头处皱折局部紊乱、溶解、消失,突触前膜囊泡减少,线粒体等细胞器空泡化等超微结构改变,而中药干预(健脾祛湿方)能够改善上述病理改变,提示中药干预(健脾祛湿方)具有一定的减轻、改善实验性自身免疫性重症肌无力动物模型的肌细胞损伤作用。
2.3 A组肌肉线粒体OGG1、NTH1、MPG的表达均最低,而B组OGG1、NTH1、MPG的表达均很高,与A组相比具有极显著差异(P＜0.01)。C组OGG1、NTH1、MPG的表达较B组极显著降低(P＜0.01),但仍极显著地高于A组(P＜0.01)。而D、E组OGG1、NTH1、MPG的表达明显升高,与其它三组均有极显著差异(P＜0.01),而D、E组间差异不明显(P＞0.05)。
2.4 B组肌肉线粒体ATP含量明显降低,与A组相比具有极显著差异(P＜0.01);进行药物干预后,肌肉ATP含量均较B组明显提高(P＜0.05),但D、E组ATP含量均明显高于C组(P＜0.01),D组亦优于E组(P＜0.05)。
2.5 B组肌肉线粒体CCO活性、含量均明显降低,与A组相比具有极显著差异(P＜0.01);进行药物干预后,C、D、E组肌肉线粒体CCO活性、含量均较B组明显提高(P＜0.05),但D、E组提高程度明显高于C组(P＜0.01),且D组亦优于E组(P＜0.01)。
结论:
1.皮下注射鼠源性乙酰胆碱受体α亚基97～116肽段可成功制作实验性自身免疫性重症肌无力大鼠模型。
2.健脾祛湿方可改善实验性自身免疫性重症肌无力模型大鼠的肌无力症状、皮毛色泽,并能逐渐增加大鼠体重。
3.健脾祛湿方具有在一定程度上的减轻、改善实验性自身免疫性重症肌无力模型大鼠肌肉线粒体及神经肌肉接头处病理改变的作用。
4.健脾祛湿方干预能明显提高实验性自身免疫性重症肌无力模型大鼠肌肉线粒体DNA糖基化酶OGG1、NTH1、MPG的表达量。
5.健脾清湿方干预能明显提高实验性自身免疫性重症肌无力模型大鼠肌肉线粒体ATP含量。
6.健脾祛湿方干预能明显提高实验性自身免疫性重症肌无力模型大鼠肌肉线粒体CCO的活性及含量。
Purposes:
Myasthenia gravis is a synapse dysfunction disease between acetylcholine motorneuron and skeletal muscles.Its pathogenesy is due to acetylcholine antibodies which lead to the transmission block of neuromuscular junction. But nowaday some researches also discovered that there was muscle cell damage in myasthenia gravis,like paramorphia in mitochondria,missing of respiratory comples 1 et cetera,which could not simply be explained by the transmission block of neuromuscular junction.On the other side,my tutor-professor Liu Youzhang,applied Jianpi-qushi(JQ) decotion to treat myasthenia gravis and achieved satisfactory curative effect.Therefore this project is to carry out clinical retrospective investigation,to summarize the current situation of diagnoses and treatment of myasthenia gravis,to observe the effect of strengthening spleen and benefiting qi method on myasthenia gravis,and to research the pathology and pathogenesy of muscle cell damage in myasthenia gravis,filling up the pathogenesy of myasthenia gravis,to observe the effect of JQ decotion and discuss its curative effect on muscle cell damage of myasthenia gravis,to provide theory guidance for the combined treatment of Chinese medicine and western medicine.
Methods:
This project includes documentary research and experimental research.In documentary research,documents of myasthenia gravis were sorted and summarized in detail at four aspects,like knowledge of myasthenia gravis in Chinese medicine,researches on myasthenia gravis in mordern medicine,the relationship between myasthenia and muscle cell damage,researches on the models of myasthenia gravis.Experimental research consist of two parts.The first part is cases review on myasthenia gravis.The cases of myasthenia gravis in the near 10 years from the medical records department of the first affiliated hospital of Guangzhou University of Chinese medicine were to refered to.To analyse the causation,pathogenesis,symtoms,inducement,complication and treatment of myasthenia gravis.Then statistic analyses were to carry out. The curative effect of drugs of strengthening spleen and benefiting qi were to observed.The current situation of diagnoses and treatment of myasthenia gravis was to summarized.The second part was animal experimental research. 45 specific pathogen-free Lewis rats were chosen.6 of them were randomly selected into normal group(group A),which were raised normally.The rest of the rats were used to produce models of experimental autoimmune myasthenia gravis(EAMG) via subcutaneous injections of man-made synthetical peptide of acetylcholine receptorαsubunit 97～116.6 weeks later,36rats left.32 EAMG models were confirmed via electromyography,which were randomly divided into model control group(group B),prednisone group(group C),JQ decoction high dose group(group D),JQ decoction low dose group(group E).Each group contained 8 EAMG rats.2 weeks after EAMG was confirmed,drugs interference via intragastric administration began.Group C was given prednisone 5.4mg/kg body weight(BW)·d.Group D and E was given Jianpi-qingre-qushi decoction respective in the dose of 37.6mg/kg BW·d,18.8mg/kg BW·d.Group A and B were given the same amount of physiological saline.The amount of intragastric administration is 10ml/Kg BW,which was given once per day for 4 weeks.At the end of the experiment,general conditions,Lennon grade,ultrastructure of the muscle mitochondria and neuromuscular junction(NMJ) of the rats were observed. The DNA glycosylase expression,the amount of ATP,and the active and content of cytochrome oxidase(CCO) of the muscle mitochondria were detected.
Results:
1.Review on clinical study:
1.1 In in-patient of myasthenia gravis,the male female ratio was 1:1.23.The morbidity peak lied between age 31 to 50.72.73%of the patients' course were below 5 years.Most of them belonged to midrange generalized type.
1.2 Active infection prevention and control,sufficient rest,avoidance of exertion,regular drug administration,never change drug dose personally,healthy diet,and agreeable emotion played a very important role in the control and recover of the patients' condition.
1.3 Most of the tongue and pulse presentations of myasthenia gravis were light tongue,white fur,and thready pulse,which reflected the main pathogenesis of myasthenia gravis that is spleen and kidney deficiency with turbid damp inside.
1.4 The analyse of the frequency of Chinese drugs used in the treatment of myasthenia gravis showed:the most commonly used drugs was drugs that can invigorating qi and strengthening spleen.Other drugs included drugs invigorating kidney,drugs eliminating dampness,drugs activating blood circulation etc.This result accorded with the analyse of the main pathogenesis of myasthenis gravis.
2.Animal experimental research:
2.1 JQ decoction could improve the general conditions of EAMG rats,including symtoms,color and luster of their fur.The difference of BW before and after the administration was not significant between group B and C(P＞0.05).The BW of group D and E increased significantly after administration(P＜0.05),but the difference between group D and E was not significant(P＞0.05).
2.2 Electron microscope observation of muscle mitochondria and neuromuscular junction:
In EAMG rats,there were sparse mussy muscle fibre,decreasing mitochondria. And part of the winkle in NMJ were mussy,diffluent,disappeared,and uesicae in presynaptic membrane decreased,vacuolization in organelles like mitochondira existed.After administration of JQ decoction,the pathology changes mentioned above were improved,which showed JQ decoction could improve the MCD of EAMG.
2.3 The expression of OGG1,NTH1,MPG of muscle mitochondria in group A was the lowest,and those in group B is very high.The difference between group A and B was significant(P＜0.01).The expression in group C decreased significantly than group B(P＜0.01),but still higher than group A(P＜0.01).The expression in group D and E were significantly higher than the other three groups(P＜0.01),but there was no significant difference between group D and E.
2.4 The content of ATP of muscle mitochondria in group B decreased, significantly different from that in group A(P＜0.01).After the administration, the content in group C,D and E all increased,group D and E were higher than group C(P＜0.05),and group D were higher than group E(P＜0.01).
2.5 The activity and content of CCO of muscle mitochondria in group B decreased, significantly different from that in group A(P＜0.01).After the administration, the activity and content in group C,D and E all increased.Group D and E were higher than group C(P＜0.05),and group D were higher than group E(P＜0.01).
Conclusion:
1.EAMG rat models could be established via subcutaneous injections of man-made synthetical peptide of acetylcholine receptorαsubunit 97～116.
2.JQ decoction could improve the general Conditions of EAMG rats,including symtoms,color and luster of their fur,and their BW.
3.JQ decoction could improve the pathology changes in muscle mitochondria and NMJ of the EAMG rats.
4.JQ decoction could significantly improve the expression of OGG1,NTH1,MPG of muscle mitochondria in EAMG rats.
5.JQ decoction could significantly improve the amount of ATP in muscle mitochondria of the EAMG rats.
6.JQ decoction could significantly improve the activity and amount of CCO in muscle mitochondria of the EAMG rats.
重症肌无力是乙酰胆碱能运动神经元与骨骼肌之间突触功能障碍性疾病,其发病多归属于抗乙酰胆碱受体抗体的作用导致神经肌肉接头传递障碍。此外目前研究还发现,在重症肌无力的发病中往往可见肌细胞的损伤,如:线粒体的形态异常、呼吸链复合体-1缺失等等,无法用神经肌肉接头传递障碍进行简单地解释。另一方面,导师刘友章教授在临床上应用健脾祛湿方治疗重症肌无力取得了良好的疗效。因此本研究拟进行临床回顾性调查,总结重症肌无力诊治的现状,观察健脾益气方药对MG的影响及作用,并通过复制实验性自身免疫性重症肌无力动物模型,研究重症肌无力的肌细胞损伤的病理特点与其发病机制,对重症肌无力的发病机制进行补充,观察健脾祛湿方对其影响作用,探讨健脾祛湿方对防治重症肌无力的肌细胞损伤的作用机制,为中西医结合治疗重症肌无力的治疗方案提供理论指导。
方法:
本研究包括文献研究及实验研究。文献研究中,从祖国医学对重症肌无力的认识、现代医学对重症肌无力的研究、重症肌无力与肌细胞损伤的关系、重症肌无力模型的研究等四方面对重症肌无力的研究进行了详细的文献整理和总结。实验研究由两部分组成:第一部分是临床病历回顾研究,拟查阅广州中医药大学第一附属医院病案室近10年来重症肌无力的住院病历,调查分析重症肌无力住院病人的病因、病程、症状、诱因、并发症及治疗等,并进行统计学分析,观察健脾益气方药对重症肌无力的疗效,总结重症肌无力的诊治现状。第二部分是动物实验研究,选用SPF级Lewis大鼠45只,随机选取6只作为正常组(A组)正常饲养,其余39只以皮下注射人工合成的鼠源性乙酰胆碱α亚基97～116肽段来制作实验性自身免疫性重症肌无力动物模型,第6周末造模大鼠剩下36只,经肌电图检测后,确定成模32只,再将其随机分为模型对照组(B组)、强的松组(C组)、健脾祛湿方高剂量组(D组)、健脾祛湿方低剂量组(E组),每组各8只。成模2周后开始经灌胃药物干预,A、B组给予等容量生理盐水灌胃,C组给予强的松,剂量为5.4mg/kg体重·d,D、E组给予健脾祛湿方,剂量分别为37.6g/kg体重·d、18.8g/kg体重·d。以上各组灌胃液体量为10ml/kg体重,每日给药一次,其浓度及等效剂量按体重折算,共给药4周。实验结束后观察大鼠一般情况及体重、Lennon评分变化,观察肌肉线粒体及神经肌肉接头处超微结构的变化,并检测肌肉线粒体的DNA糖基化酶的表达、ATP含量、细胞色素氧化酶的活性及含量的改变。
结果:
1.临床回顾性研究:
1.1重症肌无力住院患者男女比例1:1.23,发病高峰在31到50岁之间,大部分(72.73%)的病人病程在5年以下,分型以中度全身型为主;
1.2积极预防控制感染,充分休息,避免劳累,规律服药,不擅自改变药量,饮食健康,调畅情志对MG病情的控制和恢复具有重要作用;
1.3重症肌无力患者的舌脉以淡舌、白苔、细脉最多见,反映其主要病机为脾肾虚损,湿浊内停;
1.4对重症肌无力患者中药使用频次分析表明:药物使用以补气健脾药为主,辅以利湿、补肾、活血、强筋药,符合对重症肌无力主要病机的分析。
2.动物实验研究:
2.1中药干预(健脾祛湿方)可改善实验性自身免疫性重症肌无力模型大鼠的肌无力症状、皮毛色泽;治疗前后体重比较,B组体重稍下降,C组略增加,但均无明显差异(P＞0.05),D、E组体重均较治疗前明显增加(P＜0.05),D、E组间比较无明显差异(P＜0.05)。
2.2肌肉线粒体及神经肌肉接头处电镜观察:实验性自身免疫性重症肌无力模型大鼠存在肌纤维稀疏、紊乱,线粒体减少,神经肌肉接头处皱折局部紊乱、溶解、消失,突触前膜囊泡减少,线粒体等细胞器空泡化等超微结构改变,而中药干预(健脾祛湿方)能够改善上述病理改变,提示中药干预(健脾祛湿方)具有一定的减轻、改善实验性自身免疫性重症肌无力动物模型的肌细胞损伤作用。
2.3 A组肌肉线粒体OGG1、NTH1、MPG的表达均最低,而B组OGG1、NTH1、MPG的表达均很高,与A组相比具有极显著差异(P＜0.01)。C组OGG1、NTH1、MPG的表达较B组极显著降低(P＜0.01),但仍极显著地高于A组(P＜0.01)。而D、E组OGG1、NTH1、MPG的表达明显升高,与其它三组均有极显著差异(P＜0.01),而D、E组间差异不明显(P＞0.05)。
2.4 B组肌肉线粒体ATP含量明显降低,与A组相比具有极显著差异(P＜0.01);进行药物干预后,肌肉ATP含量均较B组明显提高(P＜0.05),但D、E组ATP含量均明显高于C组(P＜0.01),D组亦优于E组(P＜0.05)。
2.5 B组肌肉线粒体CCO活性、含量均明显降低,与A组相比具有极显著差异(P＜0.01);进行药物干预后,C、D、E组肌肉线粒体CCO活性、含量均较B组明显提高(P＜0.05),但D、E组提高程度明显高于C组(P＜0.01),且D组亦优于E组(P＜0.01)。
结论:
1.皮下注射鼠源性乙酰胆碱受体α亚基97～116肽段可成功制作实验性自身免疫性重症肌无力大鼠模型。
2.健脾祛湿方可改善实验性自身免疫性重症肌无力模型大鼠的肌无力症状、皮毛色泽,并能逐渐增加大鼠体重。
3.健脾祛湿方具有在一定程度上的减轻、改善实验性自身免疫性重症肌无力模型大鼠肌肉线粒体及神经肌肉接头处病理改变的作用。
4.健脾祛湿方干预能明显提高实验性自身免疫性重症肌无力模型大鼠肌肉线粒体DNA糖基化酶OGG1、NTH1、MPG的表达量。
5.健脾清湿方干预能明显提高实验性自身免疫性重症肌无力模型大鼠肌肉线粒体ATP含量。
6.健脾祛湿方干预能明显提高实验性自身免疫性重症肌无力模型大鼠肌肉线粒体CCO的活性及含量。
Purposes:
Myasthenia gravis is a synapse dysfunction disease between acetylcholine motorneuron and skeletal muscles.Its pathogenesy is due to acetylcholine antibodies which lead to the transmission block of neuromuscular junction. But nowaday some researches also discovered that there was muscle cell damage in myasthenia gravis,like paramorphia in mitochondria,missing of respiratory comples 1 et cetera,which could not simply be explained by the transmission block of neuromuscular junction.On the other side,my tutor-professor Liu Youzhang,applied Jianpi-qushi(JQ) decotion to treat myasthenia gravis and achieved satisfactory curative effect.Therefore this project is to carry out clinical retrospective investigation,to summarize the current situation of diagnoses and treatment of myasthenia gravis,to observe the effect of strengthening spleen and benefiting qi method on myasthenia gravis,and to research the pathology and pathogenesy of muscle cell damage in myasthenia gravis,filling up the pathogenesy of myasthenia gravis,to observe the effect of JQ decotion and discuss its curative effect on muscle cell damage of myasthenia gravis,to provide theory guidance for the combined treatment of Chinese medicine and western medicine.
Methods:
This project includes documentary research and experimental research.In documentary research,documents of myasthenia gravis were sorted and summarized in detail at four aspects,like knowledge of myasthenia gravis in Chinese medicine,researches on myasthenia gravis in mordern medicine,the relationship between myasthenia and muscle cell damage,researches on the models of myasthenia gravis.Experimental research consist of two parts.The first part is cases review on myasthenia gravis.The cases of myasthenia gravis in the near 10 years from the medical records department of the first affiliated hospital of Guangzhou University of Chinese medicine were to refered to.To analyse the causation,pathogenesis,symtoms,inducement,complication and treatment of myasthenia gravis.Then statistic analyses were to carry out. The curative effect of drugs of strengthening spleen and benefiting qi were to observed.The current situation of diagnoses and treatment of myasthenia gravis was to summarized.The second part was animal experimental research. 45 specific pathogen-free Lewis rats were chosen.6 of them were randomly selected into normal group(group A),which were raised normally.The rest of the rats were used to produce models of experimental autoimmune myasthenia gravis(EAMG) via subcutaneous injections of man-made synthetical peptide of acetylcholine receptorαsubunit 97～116.6 weeks later,36rats left.32 EAMG models were confirmed via electromyography,which were randomly divided into model control group(group B),prednisone group(group C),JQ decoction high dose group(group D),JQ decoction low dose group(group E).Each group contained 8 EAMG rats.2 weeks after EAMG was confirmed,drugs interference via intragastric administration began.Group C was given prednisone 5.4mg/kg body weight(BW)·d.Group D and E was given Jianpi-qingre-qushi decoction respective in the dose of 37.6mg/kg BW·d,18.8mg/kg BW·d.Group A and B were given the same amount of physiological saline.The amount of intragastric administration is 10ml/Kg BW,which was given once per day for 4 weeks.At the end of the experiment,general conditions,Lennon grade,ultrastructure of the muscle mitochondria and neuromuscular junction(NMJ) of the rats were observed. The DNA glycosylase expression,the amount of ATP,and the active and content of cytochrome oxidase(CCO) of the muscle mitochondria were detected.
Results:
1.Review on clinical study:
1.1 In in-patient of myasthenia gravis,the male female ratio was 1:1.23.The morbidity peak lied between age 31 to 50.72.73%of the patients' course were below 5 years.Most of them belonged to midrange generalized type.
1.2 Active infection prevention and control,sufficient rest,avoidance of exertion,regular drug administration,never change drug dose personally,healthy diet,and agreeable emotion played a very important role in the control and recover of the patients' condition.
1.3 Most of the tongue and pulse presentations of myasthenia gravis were light tongue,white fur,and thready pulse,which reflected the main pathogenesis of myasthenia gravis that is spleen and kidney deficiency with turbid damp inside.
1.4 The analyse of the frequency of Chinese drugs used in the treatment of myasthenia gravis showed:the most commonly used drugs was drugs that can invigorating qi and strengthening spleen.Other drugs included drugs invigorating kidney,drugs eliminating dampness,drugs activating blood circulation etc.This result accorded with the analyse of the main pathogenesis of myasthenis gravis.
2.Animal experimental research:
2.1 JQ decoction could improve the general conditions of EAMG rats,including symtoms,color and luster of their fur.The difference of BW before and after the administration was not significant between group B and C(P＞0.05).The BW of group D and E increased significantly after administration(P＜0.05),but the difference between group D and E was not significant(P＞0.05).
2.2 Electron microscope observation of muscle mitochondria and neuromuscular junction:
In EAMG rats,there were sparse mussy muscle fibre,decreasing mitochondria. And part of the winkle in NMJ were mussy,diffluent,disappeared,and uesicae in presynaptic membrane decreased,vacuolization in organelles like mitochondira existed.After administration of JQ decoction,the pathology changes mentioned above were improved,which showed JQ decoction could improve the MCD of EAMG.
2.3 The expression of OGG1,NTH1,MPG of muscle mitochondria in group A was the lowest,and those in group B is very high.The difference between group A and B was significant(P＜0.01).The expression in group C decreased significantly than group B(P＜0.01),but still higher than group A(P＜0.01).The expression in group D and E were significantly higher than the other three groups(P＜0.01),but there was no significant difference between group D and E.
2.4 The content of ATP of muscle mitochondria in group B decreased, significantly different from that in group A(P＜0.01).After the administration, the content in group C,D and E all increased,group D and E were higher than group C(P＜0.05),and group D were higher than group E(P＜0.01).
2.5 The activity and content of CCO of muscle mitochondria in group B decreased, significantly different from that in group A(P＜0.01).After the administration, the activity and content in group C,D and E all increased.Group D and E were higher than group C(P＜0.05),and group D were higher than group E(P＜0.01).
Conclusion:
1.EAMG rat models could be established via subcutaneous injections of man-made synthetical peptide of acetylcholine receptorαsubunit 97～116.
2.JQ decoction could improve the general Conditions of EAMG rats,including symtoms,color and luster of their fur,and their BW.
3.JQ decoction could improve the pathology changes in muscle mitochondria and NMJ of the EAMG rats.
4.JQ decoction could significantly improve the expression of OGG1,NTH1,MPG of muscle mitochondria in EAMG rats.
5.JQ decoction could significantly improve the amount of ATP in muscle mitochondria of the EAMG rats.
6.JQ decoction could significantly improve the activity and amount of CCO in muscle mitochondria of the EAMG rats.
引文
[1]王丽慧.古代痿证名实考[J].上海中医药杂志,2003;37(2):45-47.
[2]王丽慧.《黄帝内经》痿证考[J].中医文献杂志,2002;(4):26-27.
[3]王永炎.中医内科学[M],上海:上海科学技术出版社,1997,第一版:363.
[4]国家中医药管理局.中华人民共和国中医药行业标准·中医病证诊断疗效标准.中国标准出版社,1994.
[5]倪世秋,王继明.痿证古代文献综述[J].医学信息,2008;21(3):431-435.
[6]许健鹏,肖淑杰.中国传统医学对老年痿证认识的源流[J].黑龙江中医药,1993;(5):13-14.
[7]张世平.邓铁涛教授治疗重症肌无力之经验总结[J].广州中医学院学报,1991;8(23):70-74.
[8]邓铁涛.邓铁涛医集[M],北京:人民卫生出版社,1995,第一版:62.
[9]徐志伟,李俊德.邓铁涛学术思想研究[M],北京:华夏出版社,2001,第一版:220.
[10]马耀茹,窦建卫.重症肌无力中医病机证治初探[J].陕西中医函授,1997;(4):14-15.
[11]李庚和.脾肾学说对重症肌无力症的探讨[J].新中医,1982;(4):8-12.
[12]周慎.重症肌无力从肝论治.中医杂志[J],1995;36(9):568.
[13]苏卫东,杨晓黎.从肝论治重症且八无力的几点看法[J].辽宁中医杂志,2005;32(10):1022-1023.
[14]陈贯一.重症肌无力371例治疗体会[J].浙江中医杂志,1988;(2):64.
[15]李文广.辨治重症肌无力的探讨[J].光明中医,2003;18(3):封2.
[16]许凤全.吴以岭教授从奇经和络脉论治重症肌无力经验撷萃[J].四川中医,2006;24(2):4-6.
[17]陈金亮,许凤全.从奇经论治重症肌无力120例临床报告[J].光明中医,2000;15(4):44.
[18]杨颖.从奇经论治重症肌无力的探讨[J].实用中医药杂志,2004;20(1):40-41.
[19]郑开梅.孙慎初治疗重症肌无力经验[J].上海中医药杂志,2005;39(7):19-20.
[20]况时祥.补脾益肾法为主治疗重症肌无力[J].湖北中医杂志.2004;26(5):29-30.
[21]吴快英,冷辉林.补气健脾法治疗眼肌型重症肌无力38例分析[J].实用中医内科杂志,2003;17(5):402.
[22]刘少云.尚尔寿教授诊治重症肌无力经验摭拾[J].中医药学刊,2001; 19(1):306.
[23]张宏伟,左淑英,刘丽.从肝论治重症肌无力63例体会[J].现代中西医结合杂志,2002;11(4):337.
[24]许凤全,陈金亮,胡军勇,等.重肌灵系列制剂治疗重症肌无力300例[J].中国中医药科技,2001;8(5):333.
[25]李文广.辨证治疗重症肌无力21例[J].光明中医,2004;19(5):38.
[26]陈济东,陈贯一.辨证治疗重症肌无力216例[J].浙江中医学院学报,2003;27(1):34-35.
[27]李玉杰.“益气活血柔肝汤”治疗重症肌无力[J].江苏中医药,2002;23(3):7.
[28]汪绍先,马巍.复方健肌丸治疗重症肌无力102例报告[J].福建医药杂志,2001;23(4):76-77.
[29]李成文,露红,李增富.复肌康治疗重症肌无力90例分析[J].中医药学刊,2003;21(7):1164-1165.
[30]李方,李忠伟.补中益气汤内服配合中药制剂穴位注射治疗重症肌无力62例[J].安徽中医临床杂志,2001;13(1):40.
[31]沈毅,马文杰,陈莉莉.67例重症肌无力发病特点与中医辨证论治[J].医药世界,2007:(1):86-88.
[32]王维治,罗祖明等.神经病学[M],北京:人民卫生出版社,2002,第四版:283-287.
[33]Limburg PC,The TH,Hummel-Tappel E,et al.Antiacetylcholine receptor antibodies in myasthenia gravis.Part 1.Relation-to clinical parameters in 250 patients[J].J Neurol-Sci,1983;58:357-370.
[34]Rapoport B,Port olano S,McLachlan SM,et al.Combinational libraries:new insight into organ-specific autoantibodies.Immunol Today,1995;16:43-49.
[35]Melms A,Schalka BCG,Kirchner TH,et al.Thymus in myasthenia gravis.Isolation of T-lymphocyte lines specified for the nicotinic acetylchoine receptor from thymus of myastheniagravis[J].J Clin Invest,1988;81:902-908.
[36]Zhang GX,Xiao BG,Yu LY,et al.Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell response to AchR[J].Neuroimmunol,2001;113(1):10-18.
[37]Duan RS,Wang HB,Yang JS,et al.Anti-TNF-α antibody suppress the development of experimental autoimmune myasthenia gravis[J].Autoimmunity,2002;19(4):169-174.
[38]Vandiedonck C,Beaurain C,Ciraud M,et al.Pleiotropic effects of the 8.1HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia[J].Proc Natl Acad Sci USA,2004;101:15464-15469.
[39]王秀云,许贤豪,孙宏等.重症肌无力患者的临床绝对评分法和相对评分法[J].中华神经科杂志,1997;37:87.
[40]丛志强.重症肌无力的临床记分量表[J].临床脑电图学杂志,1993;2:18.
[41]项全申.实用小儿神经病学[M],北京:人民卫生出版社,1998,第一版:419.
[42]张星虎,许贤豪,刘个志等.新斯的明试验结果判定标准及其临床应用[J].中国神经免疫学和神经病学杂志,2000;7:197.
[43]陈清棠,余宗颐.临床神经病学[M],北京:北京科学技术出版社,2000,第1版:780-785.
[44]崔丽英,刘明生.重症肌无力的电生理诊断[J].中国实用内科杂志,2006,26(4):249-251.
[45]张朝东,刘嘉晖.重症肌无力的诊断和鉴别诊断[J].临床内科杂志,2005:22(6):367-370.
[46]潘铁成,杨明山.胸腺疾病[M],北京:人民卫生出版社,2002,第一版:134-170.
[47]杨明山,方思羽,阮旭中.神经科急症诊断治疗学[M],武汉:湖北科学技术出版社,1995,第一版:403-416.
[48]许贤豪.神经免疫学[M],北京:北京医科大学中国协和医科大学出版社,1992,第二版:113-149.
[49]Meriggioli MN,Rowin J,Richman JG,et al.Mycophenolate mofetil for myasthenia gravis:a doubleblind,p]acebo-controlled pilot study[J].Ann N Y Acad Sci,2003;998:494-499.
[50]Nagane Y,Utsugisawa K,Obara D et al.Efficacy of low-dose FK506 in the treatment of Myasthenia gravis-a randomized pilot study[J].Eur Neurol,2005;53(3):146-150.
[51]Romi F,Skeie GO,Aarli JA,et.al.Muscle autoantibodies in subgroups of myasthenia gravis patients[J].Neurol,2000;247:369-375.
[52]都爱莲,任惠民,吕传真等.25kD蛋白在人骨骼肌中的定位及在人其他组织中的表达[J].神经解剖学杂志,2004;20(2):132-136.
[53]任惠民,吕传真,周志刚等.重症肌无力患者骨骼肌25000蛋白含量分析[J].中华神经科杂志,2002;35:32-35.
[54]都爱莲,任惠民,吕传真.人骨骼叽特异性25 kD蛋白在重症肌无力患者中表达特异性减少[J].中华医学杂志.2004;84:103-106.
[55]Luebke E,Freiburg A,Skeie GO,et al.Striational autoantibodies in myasthenia gravis patients recognize I-band titin epitopes[J].J Neuroimmunol,1998;81(8):98-108.
[56]Romi F,Skeie GO,Aarli JA,et al.The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies[J].Arch Neurol,2000:57(11):1596-1600.
[57]Romi F,Skeie GO,Vedeler C,et al.Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis.A study of IgG subclasses and clinical correlations[J].J Neuroimmunol,2000;111(1-2):169-176.
[58]李延峰,李永红,管宇宙等.重症肌无力相关抗体的临床意义[J].中华神经科杂志.2007;40(1):27-30.
[59]Aarli JA.Titin,thymoma,and myasthenia gravis[J].Arch Neurol,2001;58:869-870.
[60]Valenzuela DM,Sitt TN,Distefano PS,et al.Receptor tyrosine kinase specific for the skeletal muscle lineage:expression in embryonic muscle,at the neuromuscular junction,and after injury[]].Neuron,1995;15:573-584.
[61]Liyanage Y,Hoch W,Beeson D,et al.The agrin/musclespecific kinase pathway:new targets for autoimmune and genetic disorders at the neuromuscular junction[J].Muscle Nerve,2002;25:4-16.
[62]Oh s.j.,Hatanaka Y.,Hemmi S.et al.Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis[J].Muscle Nerve,2006;33(4):500-504.
[63]Selcen D,Fukuda T,Shen XM,et al.Are MuSK antibodies the primary cause of myasthenic symptoms?[J].Neurology,2004;62:1945-1950.
[64]Bloch,RJ.Dispersal and reformation of acetylcholine receptor clusters of cultured rat myotubes treated with inhibitors of energy metabolism[]].J.Cell Biol,1979;82:626-643.
[65]Finsterer J,Oberman I,Reitner A.Respiratory chain complex-I defect mimicking myasthenia[J].Metab Brain Dis,2002;17(1):41-46.
[66]Shichijo K,Mitsui T,Kunishige M,et al.lnvolvement of mitochondria in myasthenia graviscomplicated with dermatomyositis and rheumatoid arthritis:a case report[J].Acta Neuropathol(Berl).2005;109(5):539-542.
[67]Plewnia K,Dotti MT,Malandrini A,et al.A rareassoci-ation of myasthenia gravis and mitochondrial myopathy:a clinical,biochemical and morphologic study of one case[J].J Submicrosc Cytol Pathol,1997;29(3):335-338.
[68]朱克军,汪振诚,王学敏.线粒体DNA修复系统相关酶的研究进展[J].遗传,2004;26(2):274-282.
[69]Hoodemaekers AC,Verschuuren JJ,Spaans F,et al.Age-related susceptibility to expexperimental autoirnmune myasthenia gravis:immunological and electrophysiological aspects[J].Muscle Nerve,1997;20(9):1091-1101.
[70]Lee KW,Lee SH,Kim HJ,et al.Experimental autoimmune myasthenia gravis and CDS+B-lymphocyte expression[J].J Korean Med Sci,1999;14(1):75-79.
[71]杨春晓.实验性自身免疫性重症肌无力模型的制备[J].中国临床康复,2006;10(28):116-122.
[72]徐浩鹏.丁氏双鳍电鳐电器官烟碱样乙酰胆碱受体的分离提纯[J].生物与物理学报,1984:16(1):50-55.
[73]Paas-Rozner M,Dayan M,Paas Y,et al.Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice[J].Proc Natl Acad Sci USA,2000;97(5):2168-2173.
[74]Goluszko E,Hjelmstrom P,Deng C,et al.Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis[J].J Neuroimmunol,2001;113:109-118.
[75]Vincent A,Jacobson L,Shillito P.Response to human acetylcholine receptor α 138-167:determinant spreading initiates autoimmunity to self-antigen in rabbits[J].Immunol lett,1994;39(10):269-275.
[76]Baggi F,Annoni A,Ubiali F,et.al.Breakdown of tolerance to a self-peptide of acetylcholine receptor α-subunit induces experimental myasthenia gravis in rats[J].J of immunology,2004;172:2697-2703.
[77]Oshima M,Pachner AR,Atassi MZ.Molprofile of the regions of acetylcholine receptor alpha chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor[J].Immunology,1994;31(11):833-843.
[78]Schonbeck S,Padberg F,Hoh Ifeld R,et al.Transplantation of thymicau to immune Microenvironment to severe combined immunodeficiency mice.A new model of myasthenia gravis[J].J Clin Invest,1992;90(1):245-250.
[79]许贤豪.加强重症肌无力临床和基咄的协作研究[J].中国神经免疫学和神经病学杂志,2000;7(4):195-196.
[80]王维治.神经病学[M],北京,人民卫生出版社,2001,第四版:283.
[81]许文华,韩莹莹,汪思应,等.鼠源乙酰胆碱受体α亚基97—116肽段免疫Lewis 鼠诱导实验性重症肌无力模型[J].中国神经精神疾病杂志,2006,32:179-180.
[82]Lennon VL,Lindstrom JM,Seybold ME.Experimental autoimmune myasthenia:a model of myasthenia gravis rats and guinea pigs[J].J Exp Med,1975;141(6):1365-1372.
[83]Deng C,Goluszko E,Tuzun E,et al.Resistance to experimental autoimmune myasthenia gravis in IL-6-dificient mice is associated with reduced germinal center formation and C3 production[J].J Immunol,2002;169(2):1077-1083.
[84]Sanders DB,Schleifer LS,Eldefrawi ME,et al.An immunologically induced defect of neuromuscular transmission in rats and rabbits[J].Ann NY Acad Sci,1976;274:319-336.
[85]王云甫,孙圣刚,曹学兵,等.实验性重症肌无力大鼠模型研究[J].中国神经免疫学和神经病学杂志,2003;10(4):242-245.
[86]陈奇.中药药理实验方法[M],北京:人民卫生出版社,1994,第一版:206.
[87]Christadoss P,Poussin M,Deng C.Animal models of myasthenia grayis[J].Clin Immunol,2000;94:75-87.
[88]景筠,贾建平,马山,等.重症肌无力患者胸腺乙酰胆碱受体亚单位基因的表达[J].中华神经科杂志,2005;38:322-323.
[89]Tzartos SJ,Barkas T,Cung MT,et al.Anatomy of the antigenic structure of a large membrane antigen,the muscle-type nicotinie acytylcholine receptor[J].Immunol Rev,1998;163:89-120.
[90]Link H,Xiao BG.Rat model as tool to develop new immunotherapies[J].Immunol Rev,2001;184:117.
[91]Lennon VA,McComick DJ,Lambert EH,et al.Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis,T-cell immunity,and modulating autoantibodies[J].Proc Nail Acad Sci USA,1985;82(24):8805.
[92]Lennon VA,Griesmann GA,McComick DJ,et al.Definition of myasthengenic sites of the human acetylcholine receptor using synthetic peptides[J].Ann N.Y.Acad Sci,1987;505:439-450.
[93]Baggi F,Annoni A,Ubiali F,et al.Torpedo-derived 97-116 peptide of the AchR α -subunit induces experimental myasthenia gravis in Lewis rat[J].Ann N.Y.Acad Sci,2003:998:391-394.
[94]吴怀国,陈荣志,许文华等.乙酰胆碱受体α亚基125～147肽段制作实验性重症肌无力动物模型的研究[J].临床神经病学研究,2006;19(5):368-370.
[95]杨丽,程焱.乙酰胆碱受体α亚单位125～147段多肽致实验性自身免疫性重症肌无力[J].中华神经科杂志,2003;36(1):32-34.
[96]Yoshikawa H,Iwasa K,Satoh K,ea al.FK506 prevents induction of rat experimental autoimmune myasthenia graivs[J].J Autoimmun,1997;10:11-16.
[97]孙巍,张静生,刘萍等.实验性自身免疫性重症肌无力(EAMG)大鼠模型的研究 [J].中医药学刊,2005;23(5):812-814.
[98]Clayton D A,Doda J N,Friedberg E C.The absence of a pyrimidine dimer repair mechanism in mammalian mitochondria[J].Proc Natl Acad Sci USA,1974;71:2777-2781.
[99]LeDoux S P,Wilson G L,Beecham B J,Stevnsner T,Wassermann K,Bohr V A.Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary Cells[J].Carcinogenesis,1992;13:1967-1973.
[100]Singh K K,SigMa B,Sikder H A,et al.Inactivation of Saceharomyces cerevisiae OGG1 DNA repair gene leads to an increased frequency of mituehondrial mutants[J].Nucleic Acid Res,2001;29(6):1381-1388.
[101]Luna L,Bjoras M,Ha E,et al.Cell cycle regulation,intraeellular sorting and induced overexpression of the human NTH1 DNA glycosylase involved in removal,of formamidopyrimidine residues from DNA[J].Murat Res,2000;460(2):95-104.
[102]Wei Y H,Lee H C.Oxidative stress,mitochondrial DNA mutation,and impairment of antioxidant enzymes in aging[J].Exp Biol Med(Maywood),2002;227(9):671-682.
[103]曾升海,田惠民.邓铁涛教授治疗重症肌无力的经验介绍[J].陕西中医,2000;21(12):559-560.
[104]李顺民.邓铁涛治疗重症肌无力的思路与方法[J].实用中西医结合杂志,1991;4(11):664-665.
[105]刘友章,宋雅芳,蓝海等.重症肌无力脾虚湿热病机探析[J].中华中医药学刊,2008:26(2):229-230.
[106]Liu Youzhang.An Exploration of the Nature of "Spleen" in Traditional Chinese Medicine on a Subcellular level:A Study on the Gastric Mucosal Ultrastructure of 51 cases[J].Traditional Chinese Medicine Digest,1987;11(3):4-20.
[107]Xiang Min-Yu,You Zhang Liu,toru Noda and Kazuo Ogawa.Chinese Traditional Medicine protects Gastric cells from Adriamycin cytotoxicity[J].Acta Histochem,1995;28(6):539-547.
[108]于向民,刘友章.阿霉素对大鼠肝细胞的毒性及中药六君子汤对肝细胞的保护作用[J].解剖学报,1996;27(1):79.
[109]刘友章,王昌俊,周俊亮等.长期脾虚模型大鼠细胞线粒体的研究[J].中医药学刊,2006;24(3):391-394.
[110]徐升,刘友章,杨晓军.从脾胃论治重症肌无力[J].山东中医杂志,2006; 25(11):727-728.
[111]刘春玲,徐鸿华,吴清和等.五指毛桃对小鼠免疫功能影响的实验研究[J].中药材,2004;27(5):367-368.
[112]宋东林,吕强,石进等.实验性重症肌无力大鼠神经肌肉接头处超微结构的研究[J].中华神经精神科杂志,1994;27(3):135-137.
[113]宋东林,石进,刘翠兰等.重症肌无力患者神经肌肉接头处的超微结构研究[J].中华神经科杂志,1998;31(5):299-301.
[114]宋东林,石进,吕强等.重症肌无力和癌性肌病的神经肌肉接头处变化特点[J].中风与神经疾病杂志,1998;15(3):148-150.
[115]刘睿,李柱一,张琪等.重症肌无力大鼠膈肌运动终板的形态学研究[J].第四军医大学学报,2005;26(2):112-114.
[2]王丽慧.《黄帝内经》痿证考[J].中医文献杂志,2002;(4):26-27.
[3]王永炎.中医内科学[M],上海:上海科学技术出版社,1997,第一版:363.
[4]国家中医药管理局.中华人民共和国中医药行业标准·中医病证诊断疗效标准.中国标准出版社,1994.
[5]倪世秋,王继明.痿证古代文献综述[J].医学信息,2008;21(3):431-435.
[6]许健鹏,肖淑杰.中国传统医学对老年痿证认识的源流[J].黑龙江中医药,1993;(5):13-14.
[7]张世平.邓铁涛教授治疗重症肌无力之经验总结[J].广州中医学院学报,1991;8(23):70-74.
[8]邓铁涛.邓铁涛医集[M],北京:人民卫生出版社,1995,第一版:62.
[9]徐志伟,李俊德.邓铁涛学术思想研究[M],北京:华夏出版社,2001,第一版:220.
[10]马耀茹,窦建卫.重症肌无力中医病机证治初探[J].陕西中医函授,1997;(4):14-15.
[11]李庚和.脾肾学说对重症肌无力症的探讨[J].新中医,1982;(4):8-12.
[12]周慎.重症肌无力从肝论治.中医杂志[J],1995;36(9):568.
[13]苏卫东,杨晓黎.从肝论治重症且八无力的几点看法[J].辽宁中医杂志,2005;32(10):1022-1023.
[14]陈贯一.重症肌无力371例治疗体会[J].浙江中医杂志,1988;(2):64.
[15]李文广.辨治重症肌无力的探讨[J].光明中医,2003;18(3):封2.
[16]许凤全.吴以岭教授从奇经和络脉论治重症肌无力经验撷萃[J].四川中医,2006;24(2):4-6.
[17]陈金亮,许凤全.从奇经论治重症肌无力120例临床报告[J].光明中医,2000;15(4):44.
[18]杨颖.从奇经论治重症肌无力的探讨[J].实用中医药杂志,2004;20(1):40-41.
[19]郑开梅.孙慎初治疗重症肌无力经验[J].上海中医药杂志,2005;39(7):19-20.
[20]况时祥.补脾益肾法为主治疗重症肌无力[J].湖北中医杂志.2004;26(5):29-30.
[21]吴快英,冷辉林.补气健脾法治疗眼肌型重症肌无力38例分析[J].实用中医内科杂志,2003;17(5):402.
[22]刘少云.尚尔寿教授诊治重症肌无力经验摭拾[J].中医药学刊,2001; 19(1):306.
[23]张宏伟,左淑英,刘丽.从肝论治重症肌无力63例体会[J].现代中西医结合杂志,2002;11(4):337.
[24]许凤全,陈金亮,胡军勇,等.重肌灵系列制剂治疗重症肌无力300例[J].中国中医药科技,2001;8(5):333.
[25]李文广.辨证治疗重症肌无力21例[J].光明中医,2004;19(5):38.
[26]陈济东,陈贯一.辨证治疗重症肌无力216例[J].浙江中医学院学报,2003;27(1):34-35.
[27]李玉杰.“益气活血柔肝汤”治疗重症肌无力[J].江苏中医药,2002;23(3):7.
[28]汪绍先,马巍.复方健肌丸治疗重症肌无力102例报告[J].福建医药杂志,2001;23(4):76-77.
[29]李成文,露红,李增富.复肌康治疗重症肌无力90例分析[J].中医药学刊,2003;21(7):1164-1165.
[30]李方,李忠伟.补中益气汤内服配合中药制剂穴位注射治疗重症肌无力62例[J].安徽中医临床杂志,2001;13(1):40.
[31]沈毅,马文杰,陈莉莉.67例重症肌无力发病特点与中医辨证论治[J].医药世界,2007:(1):86-88.
[32]王维治,罗祖明等.神经病学[M],北京:人民卫生出版社,2002,第四版:283-287.
[33]Limburg PC,The TH,Hummel-Tappel E,et al.Antiacetylcholine receptor antibodies in myasthenia gravis.Part 1.Relation-to clinical parameters in 250 patients[J].J Neurol-Sci,1983;58:357-370.
[34]Rapoport B,Port olano S,McLachlan SM,et al.Combinational libraries:new insight into organ-specific autoantibodies.Immunol Today,1995;16:43-49.
[35]Melms A,Schalka BCG,Kirchner TH,et al.Thymus in myasthenia gravis.Isolation of T-lymphocyte lines specified for the nicotinic acetylchoine receptor from thymus of myastheniagravis[J].J Clin Invest,1988;81:902-908.
[36]Zhang GX,Xiao BG,Yu LY,et al.Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell response to AchR[J].Neuroimmunol,2001;113(1):10-18.
[37]Duan RS,Wang HB,Yang JS,et al.Anti-TNF-α antibody suppress the development of experimental autoimmune myasthenia gravis[J].Autoimmunity,2002;19(4):169-174.
[38]Vandiedonck C,Beaurain C,Ciraud M,et al.Pleiotropic effects of the 8.1HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia[J].Proc Natl Acad Sci USA,2004;101:15464-15469.
[39]王秀云,许贤豪,孙宏等.重症肌无力患者的临床绝对评分法和相对评分法[J].中华神经科杂志,1997;37:87.
[40]丛志强.重症肌无力的临床记分量表[J].临床脑电图学杂志,1993;2:18.
[41]项全申.实用小儿神经病学[M],北京:人民卫生出版社,1998,第一版:419.
[42]张星虎,许贤豪,刘个志等.新斯的明试验结果判定标准及其临床应用[J].中国神经免疫学和神经病学杂志,2000;7:197.
[43]陈清棠,余宗颐.临床神经病学[M],北京:北京科学技术出版社,2000,第1版:780-785.
[44]崔丽英,刘明生.重症肌无力的电生理诊断[J].中国实用内科杂志,2006,26(4):249-251.
[45]张朝东,刘嘉晖.重症肌无力的诊断和鉴别诊断[J].临床内科杂志,2005:22(6):367-370.
[46]潘铁成,杨明山.胸腺疾病[M],北京:人民卫生出版社,2002,第一版:134-170.
[47]杨明山,方思羽,阮旭中.神经科急症诊断治疗学[M],武汉:湖北科学技术出版社,1995,第一版:403-416.
[48]许贤豪.神经免疫学[M],北京:北京医科大学中国协和医科大学出版社,1992,第二版:113-149.
[49]Meriggioli MN,Rowin J,Richman JG,et al.Mycophenolate mofetil for myasthenia gravis:a doubleblind,p]acebo-controlled pilot study[J].Ann N Y Acad Sci,2003;998:494-499.
[50]Nagane Y,Utsugisawa K,Obara D et al.Efficacy of low-dose FK506 in the treatment of Myasthenia gravis-a randomized pilot study[J].Eur Neurol,2005;53(3):146-150.
[51]Romi F,Skeie GO,Aarli JA,et.al.Muscle autoantibodies in subgroups of myasthenia gravis patients[J].Neurol,2000;247:369-375.
[52]都爱莲,任惠民,吕传真等.25kD蛋白在人骨骼肌中的定位及在人其他组织中的表达[J].神经解剖学杂志,2004;20(2):132-136.
[53]任惠民,吕传真,周志刚等.重症肌无力患者骨骼肌25000蛋白含量分析[J].中华神经科杂志,2002;35:32-35.
[54]都爱莲,任惠民,吕传真.人骨骼叽特异性25 kD蛋白在重症肌无力患者中表达特异性减少[J].中华医学杂志.2004;84:103-106.
[55]Luebke E,Freiburg A,Skeie GO,et al.Striational autoantibodies in myasthenia gravis patients recognize I-band titin epitopes[J].J Neuroimmunol,1998;81(8):98-108.
[56]Romi F,Skeie GO,Aarli JA,et al.The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies[J].Arch Neurol,2000:57(11):1596-1600.
[57]Romi F,Skeie GO,Vedeler C,et al.Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis.A study of IgG subclasses and clinical correlations[J].J Neuroimmunol,2000;111(1-2):169-176.
[58]李延峰,李永红,管宇宙等.重症肌无力相关抗体的临床意义[J].中华神经科杂志.2007;40(1):27-30.
[59]Aarli JA.Titin,thymoma,and myasthenia gravis[J].Arch Neurol,2001;58:869-870.
[60]Valenzuela DM,Sitt TN,Distefano PS,et al.Receptor tyrosine kinase specific for the skeletal muscle lineage:expression in embryonic muscle,at the neuromuscular junction,and after injury[]].Neuron,1995;15:573-584.
[61]Liyanage Y,Hoch W,Beeson D,et al.The agrin/musclespecific kinase pathway:new targets for autoimmune and genetic disorders at the neuromuscular junction[J].Muscle Nerve,2002;25:4-16.
[62]Oh s.j.,Hatanaka Y.,Hemmi S.et al.Repetitive nerve stimulation of facial muscles in MuSK antibody-positive myasthenia gravis[J].Muscle Nerve,2006;33(4):500-504.
[63]Selcen D,Fukuda T,Shen XM,et al.Are MuSK antibodies the primary cause of myasthenic symptoms?[J].Neurology,2004;62:1945-1950.
[64]Bloch,RJ.Dispersal and reformation of acetylcholine receptor clusters of cultured rat myotubes treated with inhibitors of energy metabolism[]].J.Cell Biol,1979;82:626-643.
[65]Finsterer J,Oberman I,Reitner A.Respiratory chain complex-I defect mimicking myasthenia[J].Metab Brain Dis,2002;17(1):41-46.
[66]Shichijo K,Mitsui T,Kunishige M,et al.lnvolvement of mitochondria in myasthenia graviscomplicated with dermatomyositis and rheumatoid arthritis:a case report[J].Acta Neuropathol(Berl).2005;109(5):539-542.
[67]Plewnia K,Dotti MT,Malandrini A,et al.A rareassoci-ation of myasthenia gravis and mitochondrial myopathy:a clinical,biochemical and morphologic study of one case[J].J Submicrosc Cytol Pathol,1997;29(3):335-338.
[68]朱克军,汪振诚,王学敏.线粒体DNA修复系统相关酶的研究进展[J].遗传,2004;26(2):274-282.
[69]Hoodemaekers AC,Verschuuren JJ,Spaans F,et al.Age-related susceptibility to expexperimental autoirnmune myasthenia gravis:immunological and electrophysiological aspects[J].Muscle Nerve,1997;20(9):1091-1101.
[70]Lee KW,Lee SH,Kim HJ,et al.Experimental autoimmune myasthenia gravis and CDS+B-lymphocyte expression[J].J Korean Med Sci,1999;14(1):75-79.
[71]杨春晓.实验性自身免疫性重症肌无力模型的制备[J].中国临床康复,2006;10(28):116-122.
[72]徐浩鹏.丁氏双鳍电鳐电器官烟碱样乙酰胆碱受体的分离提纯[J].生物与物理学报,1984:16(1):50-55.
[73]Paas-Rozner M,Dayan M,Paas Y,et al.Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice[J].Proc Natl Acad Sci USA,2000;97(5):2168-2173.
[74]Goluszko E,Hjelmstrom P,Deng C,et al.Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis[J].J Neuroimmunol,2001;113:109-118.
[75]Vincent A,Jacobson L,Shillito P.Response to human acetylcholine receptor α 138-167:determinant spreading initiates autoimmunity to self-antigen in rabbits[J].Immunol lett,1994;39(10):269-275.
[76]Baggi F,Annoni A,Ubiali F,et.al.Breakdown of tolerance to a self-peptide of acetylcholine receptor α-subunit induces experimental myasthenia gravis in rats[J].J of immunology,2004;172:2697-2703.
[77]Oshima M,Pachner AR,Atassi MZ.Molprofile of the regions of acetylcholine receptor alpha chain recognized by T-lymphocytes and by antibodies in EAMG-susceptible and non-susceptible mouse strains after different periods of immunization with the receptor[J].Immunology,1994;31(11):833-843.
[78]Schonbeck S,Padberg F,Hoh Ifeld R,et al.Transplantation of thymicau to immune Microenvironment to severe combined immunodeficiency mice.A new model of myasthenia gravis[J].J Clin Invest,1992;90(1):245-250.
[79]许贤豪.加强重症肌无力临床和基咄的协作研究[J].中国神经免疫学和神经病学杂志,2000;7(4):195-196.
[80]王维治.神经病学[M],北京,人民卫生出版社,2001,第四版:283.
[81]许文华,韩莹莹,汪思应,等.鼠源乙酰胆碱受体α亚基97—116肽段免疫Lewis 鼠诱导实验性重症肌无力模型[J].中国神经精神疾病杂志,2006,32:179-180.
[82]Lennon VL,Lindstrom JM,Seybold ME.Experimental autoimmune myasthenia:a model of myasthenia gravis rats and guinea pigs[J].J Exp Med,1975;141(6):1365-1372.
[83]Deng C,Goluszko E,Tuzun E,et al.Resistance to experimental autoimmune myasthenia gravis in IL-6-dificient mice is associated with reduced germinal center formation and C3 production[J].J Immunol,2002;169(2):1077-1083.
[84]Sanders DB,Schleifer LS,Eldefrawi ME,et al.An immunologically induced defect of neuromuscular transmission in rats and rabbits[J].Ann NY Acad Sci,1976;274:319-336.
[85]王云甫,孙圣刚,曹学兵,等.实验性重症肌无力大鼠模型研究[J].中国神经免疫学和神经病学杂志,2003;10(4):242-245.
[86]陈奇.中药药理实验方法[M],北京:人民卫生出版社,1994,第一版:206.
[87]Christadoss P,Poussin M,Deng C.Animal models of myasthenia grayis[J].Clin Immunol,2000;94:75-87.
[88]景筠,贾建平,马山,等.重症肌无力患者胸腺乙酰胆碱受体亚单位基因的表达[J].中华神经科杂志,2005;38:322-323.
[89]Tzartos SJ,Barkas T,Cung MT,et al.Anatomy of the antigenic structure of a large membrane antigen,the muscle-type nicotinie acytylcholine receptor[J].Immunol Rev,1998;163:89-120.
[90]Link H,Xiao BG.Rat model as tool to develop new immunotherapies[J].Immunol Rev,2001;184:117.
[91]Lennon VA,McComick DJ,Lambert EH,et al.Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis,T-cell immunity,and modulating autoantibodies[J].Proc Nail Acad Sci USA,1985;82(24):8805.
[92]Lennon VA,Griesmann GA,McComick DJ,et al.Definition of myasthengenic sites of the human acetylcholine receptor using synthetic peptides[J].Ann N.Y.Acad Sci,1987;505:439-450.
[93]Baggi F,Annoni A,Ubiali F,et al.Torpedo-derived 97-116 peptide of the AchR α -subunit induces experimental myasthenia gravis in Lewis rat[J].Ann N.Y.Acad Sci,2003:998:391-394.
[94]吴怀国,陈荣志,许文华等.乙酰胆碱受体α亚基125～147肽段制作实验性重症肌无力动物模型的研究[J].临床神经病学研究,2006;19(5):368-370.
[95]杨丽,程焱.乙酰胆碱受体α亚单位125～147段多肽致实验性自身免疫性重症肌无力[J].中华神经科杂志,2003;36(1):32-34.
[96]Yoshikawa H,Iwasa K,Satoh K,ea al.FK506 prevents induction of rat experimental autoimmune myasthenia graivs[J].J Autoimmun,1997;10:11-16.
[97]孙巍,张静生,刘萍等.实验性自身免疫性重症肌无力(EAMG)大鼠模型的研究 [J].中医药学刊,2005;23(5):812-814.
[98]Clayton D A,Doda J N,Friedberg E C.The absence of a pyrimidine dimer repair mechanism in mammalian mitochondria[J].Proc Natl Acad Sci USA,1974;71:2777-2781.
[99]LeDoux S P,Wilson G L,Beecham B J,Stevnsner T,Wassermann K,Bohr V A.Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary Cells[J].Carcinogenesis,1992;13:1967-1973.
[100]Singh K K,SigMa B,Sikder H A,et al.Inactivation of Saceharomyces cerevisiae OGG1 DNA repair gene leads to an increased frequency of mituehondrial mutants[J].Nucleic Acid Res,2001;29(6):1381-1388.
[101]Luna L,Bjoras M,Ha E,et al.Cell cycle regulation,intraeellular sorting and induced overexpression of the human NTH1 DNA glycosylase involved in removal,of formamidopyrimidine residues from DNA[J].Murat Res,2000;460(2):95-104.
[102]Wei Y H,Lee H C.Oxidative stress,mitochondrial DNA mutation,and impairment of antioxidant enzymes in aging[J].Exp Biol Med(Maywood),2002;227(9):671-682.
[103]曾升海,田惠民.邓铁涛教授治疗重症肌无力的经验介绍[J].陕西中医,2000;21(12):559-560.
[104]李顺民.邓铁涛治疗重症肌无力的思路与方法[J].实用中西医结合杂志,1991;4(11):664-665.
[105]刘友章,宋雅芳,蓝海等.重症肌无力脾虚湿热病机探析[J].中华中医药学刊,2008:26(2):229-230.
[106]Liu Youzhang.An Exploration of the Nature of "Spleen" in Traditional Chinese Medicine on a Subcellular level:A Study on the Gastric Mucosal Ultrastructure of 51 cases[J].Traditional Chinese Medicine Digest,1987;11(3):4-20.
[107]Xiang Min-Yu,You Zhang Liu,toru Noda and Kazuo Ogawa.Chinese Traditional Medicine protects Gastric cells from Adriamycin cytotoxicity[J].Acta Histochem,1995;28(6):539-547.
[108]于向民,刘友章.阿霉素对大鼠肝细胞的毒性及中药六君子汤对肝细胞的保护作用[J].解剖学报,1996;27(1):79.
[109]刘友章,王昌俊,周俊亮等.长期脾虚模型大鼠细胞线粒体的研究[J].中医药学刊,2006;24(3):391-394.
[110]徐升,刘友章,杨晓军.从脾胃论治重症肌无力[J].山东中医杂志,2006; 25(11):727-728.
[111]刘春玲,徐鸿华,吴清和等.五指毛桃对小鼠免疫功能影响的实验研究[J].中药材,2004;27(5):367-368.
[112]宋东林,吕强,石进等.实验性重症肌无力大鼠神经肌肉接头处超微结构的研究[J].中华神经精神科杂志,1994;27(3):135-137.
[113]宋东林,石进,刘翠兰等.重症肌无力患者神经肌肉接头处的超微结构研究[J].中华神经科杂志,1998;31(5):299-301.
[114]宋东林,石进,吕强等.重症肌无力和癌性肌病的神经肌肉接头处变化特点[J].中风与神经疾病杂志,1998;15(3):148-150.
[115]刘睿,李柱一,张琪等.重症肌无力大鼠膈肌运动终板的形态学研究[J].第四军医大学学报,2005;26(2):112-114.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |